Patents by Inventor Arejas J. Uzgiris

Arejas J. Uzgiris has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220349017
    Abstract: The present disclosure provides, among other things, primers and probes for detecting shedding of an AAV construct or fragment thereof in a subject. In some embodiments the primers are selected to generate an amplicon that comprises (i) a first strand comprising (1) a nucleotide sequence corresponding to the forward primer, and (2) a nucleotide sequence corresponding to a portion of the AAV construct or fragment thereof, (ii) a second strand comprising (1) a nucleotide sequence of the reverse primer, and (2) a nucleotide sequence that is complementary to the portion of the AAV construct or fragment thereof, or (iii) a combination thereof, where the portion of the AAV construct or fragment thereof comprises a nucleotide sequence that spans a junction between a regulatory element and the therapeutic gene of interest.
    Type: Application
    Filed: August 29, 2020
    Publication date: November 3, 2022
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Arejas J. Uzgiris, Isabelle Philipp, Xiaolei Qiu, Sara Weitz, Zuguang Wang
  • Patent number: 10968487
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: April 4, 2018
    Date of Patent: April 6, 2021
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20180223377
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: April 4, 2018
    Publication date: August 9, 2018
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Patent number: 9938584
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: April 10, 2018
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20170137894
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: January 31, 2017
    Publication date: May 18, 2017
    Applicant: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Patent number: 9605321
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: March 28, 2017
    Assignee: Siemens Healthcare Diagnostics Inc.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying
  • Publication number: 20150094231
    Abstract: Provided are oligonucleotides that are capable of detecting KRAS and PIK3CA mutations in both cancer patients and healthy individuals with high specificity in kPCR assays. When the oligonucleotides are used as forward primers in conjunction with a defined genotyping algorithm spreadsheet, the primers are capable of enhancing detection of KRAS codon 12, 13, and 61 and PIK3CA codon 542, 545, and 1047 single nucleotide polymorphisms (SNPs) in a background of wild-type sequences. The oligonucleotides of the present invention are also capable of preventing pseudogene amplification when the oligonucleotides are hybridized as reverse primers or detection probes to the mismatch sequences.
    Type: Application
    Filed: December 12, 2014
    Publication date: April 2, 2015
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.
    Inventors: Jill Detmer, Arejas J. Uzgiris, Andy Ying